FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3200851617> ?p ?o ?g. }

• W3200851617 endingPage "e2238" @default.
• W3200851617 startingPage "e2227" @default.
• W3200851617 abstract "Programmed death-1 (PD-1) and programmed death-ligand 1 (PD-L1) blockade immunotherapies have changed the landscape of cancer therapy. However, the main limitation of these therapies is the lack of definitively predictive biomarkers to predict treatment response. Whether PD-L1 expression on circulating tumor cells (CTCs) is associated with the clinical outcomes of immunotherapy remains to be extensively investigated.One hundred fifty-five patients with different advanced cancers were enrolled in this study and treated with anti-PD-1/PD-L1 monoclonal antibodies. Using the Pep@MNPs method, CTCs were isolated and enumerated. The PD-L1 expression levels were analyzed by an immunofluorescence assay for semiquantitative assessment with four categories (negative, low, medium, and high).Prior to immunotherapy, 81.93% (127/155) of patients had PD-L1-positive CTCs, and 71.61% (111/155) had at least one PD-L1-high CTC. The group with PD-L1-positive CTCs had a higher disease control rate (DCR) (71.56%, 91/127), with a DCR of only 39.29% (11/28) for the remaining individuals (p = .001). The objective response rate and DCR in PD-L1-high patients were higher than those in the other patients (32.44% vs. 13.64%, p = .018 and 75.68% vs. 40.91%, p < .0001, respectively). The reduction in the counts and ratios of PD-L1-positive CTCs and PD-L1-high CTCs reflected a beneficial response to PD-1/PD-L1 inhibitors. Furthermore, patients with PD-L1-high CTCs had significantly longer progression-free survival (4.9 vs. 2.2 months, p < .0001) and overall survival (16.1 vs. 9.0 months, p = .0235) than those without PD-L1-high CTCs.The PD-L1 level on CTCs may serve as a clinically actionable biomarker for immunotherapy, and its dynamic changes could predict the therapeutic response.This study was designed to investigate the role of programmed death-ligand 1 (PD-L1) expression on circulating tumor cells in predicting and monitoring response to programmed death-1 (PD-1)/PD-L1 blockade immunotherapies in patients with advanced cancer. The results of the study showed that PD-L1-high-expression circulating tumor cells (CTCs) were both a predictive biomarker and a prognostic factor in patients with advanced cancer treated with anti-PD-1/PD-L1 monoclonal antibodies. These observations suggest that PD-L1 level on CTCs is a potential clinical biomarker for immunotherapy." @default.
• W3200851617 created "2021-09-27" @default.
• W3200851617 creator A5017482227 @default.
• W3200851617 creator A5017833906 @default.
• W3200851617 creator A5023874610 @default.
• W3200851617 creator A5034982613 @default.
• W3200851617 creator A5036917207 @default.
• W3200851617 creator A5037672730 @default.
• W3200851617 creator A5041461630 @default.
• W3200851617 creator A5042170464 @default.
• W3200851617 creator A5062179244 @default.
• W3200851617 creator A5065081259 @default.
• W3200851617 creator A5073070877 @default.
• W3200851617 creator A5076053801 @default.
• W3200851617 creator A5078924153 @default.
• W3200851617 date "2021-09-28" @default.
• W3200851617 modified "2023-10-16" @default.
• W3200851617 title "Assessment of PD-L1 Expression on Circulating Tumor Cells for Predicting Clinical Outcomes in Patients with Cancer Receiving PD-1/PD-L1 Blockade Therapies" @default.
• W3200851617 cites W1939817548 @default.
• W3200851617 cites W1940241680 @default.
• W3200851617 cites W1982488143 @default.
• W3200851617 cites W2088942535 @default.
• W3200851617 cites W2115918781 @default.
• W3200851617 cites W2156923287 @default.
• W3200851617 cites W2160834915 @default.
• W3200851617 cites W2163814058 @default.
• W3200851617 cites W2292383635 @default.
• W3200851617 cites W2294395959 @default.
• W3200851617 cites W2347070489 @default.
• W3200851617 cites W2397958390 @default.
• W3200851617 cites W2435563082 @default.
• W3200851617 cites W2471117482 @default.
• W3200851617 cites W2507710416 @default.
• W3200851617 cites W2509481886 @default.
• W3200851617 cites W2527905628 @default.
• W3200851617 cites W2585998899 @default.
• W3200851617 cites W2604441970 @default.
• W3200851617 cites W2724136428 @default.
• W3200851617 cites W2739132742 @default.
• W3200851617 cites W2753065806 @default.
• W3200851617 cites W2763064222 @default.
• W3200851617 cites W2779221466 @default.
• W3200851617 cites W2791753645 @default.
• W3200851617 cites W2805592007 @default.
• W3200851617 cites W2885786398 @default.
• W3200851617 cites W2886963239 @default.
• W3200851617 cites W2887381926 @default.
• W3200851617 cites W2889307896 @default.
• W3200851617 cites W2897612290 @default.
• W3200851617 cites W2903835900 @default.
• W3200851617 cites W2976652879 @default.
• W3200851617 cites W2994505596 @default.
• W3200851617 cites W3008514541 @default.
• W3200851617 cites W3010911781 @default.
• W3200851617 cites W3012740949 @default.
• W3200851617 cites W3012770963 @default.
• W3200851617 doi "https://doi.org/10.1002/onco.13981" @default.
• W3200851617 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/34516729" @default.
• W3200851617 hasPublicationYear "2021" @default.
• W3200851617 type Work @default.
• W3200851617 sameAs 3200851617 @default.
• W3200851617 citedByCount "16" @default.
• W3200851617 countsByYear W32008516172022 @default.
• W3200851617 countsByYear W32008516172023 @default.
• W3200851617 crossrefType "journal-article" @default.
• W3200851617 hasAuthorship W3200851617A5017482227 @default.
• W3200851617 hasAuthorship W3200851617A5017833906 @default.
• W3200851617 hasAuthorship W3200851617A5023874610 @default.
• W3200851617 hasAuthorship W3200851617A5034982613 @default.
• W3200851617 hasAuthorship W3200851617A5036917207 @default.
• W3200851617 hasAuthorship W3200851617A5037672730 @default.
• W3200851617 hasAuthorship W3200851617A5041461630 @default.
• W3200851617 hasAuthorship W3200851617A5042170464 @default.
• W3200851617 hasAuthorship W3200851617A5062179244 @default.
• W3200851617 hasAuthorship W3200851617A5065081259 @default.
• W3200851617 hasAuthorship W3200851617A5073070877 @default.
• W3200851617 hasAuthorship W3200851617A5076053801 @default.
• W3200851617 hasAuthorship W3200851617A5078924153 @default.
• W3200851617 hasBestOaLocation W32008516171 @default.
• W3200851617 hasConcept C121608353 @default.
• W3200851617 hasConcept C126322002 @default.
• W3200851617 hasConcept C143998085 @default.
• W3200851617 hasConcept C159654299 @default.
• W3200851617 hasConcept C170493617 @default.
• W3200851617 hasConcept C203014093 @default.
• W3200851617 hasConcept C2777701055 @default.
• W3200851617 hasConcept C2778468042 @default.
• W3200851617 hasConcept C2779013556 @default.
• W3200851617 hasConcept C2781053074 @default.
• W3200851617 hasConcept C542903549 @default.
• W3200851617 hasConcept C61238886 @default.
• W3200851617 hasConcept C71924100 @default.
• W3200851617 hasConceptScore W3200851617C121608353 @default.
• W3200851617 hasConceptScore W3200851617C126322002 @default.
• W3200851617 hasConceptScore W3200851617C143998085 @default.
• W3200851617 hasConceptScore W3200851617C159654299 @default.
• W3200851617 hasConceptScore W3200851617C170493617 @default.
• W3200851617 hasConceptScore W3200851617C203014093 @default.

• next